This issue of memo inHaematology provides a comprehensive overview of groundbreaking findings in the field of hematology, including key results from relevant studies on targeted therapies presented at EHA2024. The report provides an in-depth analysis of recent advances in the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies, with insights into the use of monotherapies and combination therapies based on Bruton’s tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl2) inhibition. It includes real-world data showing favorable results for BTK inhibition in CLL and mantle cell lymphoma (MCL). In addition, the report covers the use of innovative therapies such as BTK degraders and bispecific antibodies, which have demonstrated promising efficacy in B-cell malignancies. Finally, it highlights matching-adjusted indirect comparisons as a technique that allow the assessment of new treatments vs standard treatments when direct comparisons through randomized controlled trials are not available.